The U.S. Food and Drug Administration’s approval of Auxilium Pharmaceuticals’ drug Xiaflex (NASDAQ: AUXL) makes it the first medication to treat Peyronie’s disease. It is a painful condition affecting the penis and the drug could lead to more people seeking treatment. Peyronie’s disease is a connective tissue disorder that results in the growth of fibrous plaque […]
Auxilium Phramaceuticals (NASDAQ:AUXL)‘s drug to treat Peyronie’s disease, a condition in which the penis is abnormally curved, has achieved positive phase 3 results, according to a company statement. If approved, the Malvern, Pennsylvania company’s drug Xiaflex would be the first biologic to combat the disease. The company said two one-year clinical trials to test safety […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Auxilium Pharmaceuticals (NASDAQ:AUXL) has agreed to a licensing deal valued at up to $68.5 million with Swiss pharmaceutical company, Actelion. The licensing deal for its drug, Xiaflex, for the treatment of Peyronie’s disease and Dupuytren’s contracture, will cover Canada, Brazil, Australia and Mexico. Auxilium will get $10 million initially and another $58.5 million if the […]
Auxilium Pharmaceuticals (NASDAQ:AUXL) has reshuffled its marketing and public relations team to help boost sales of its drug Xiaflex as it reported earnings for the third quarter. The Malvern, Pennsylvania drug company said it will eliminate the position of executive vice president of sales and marketing, a position held by Roger D. Graham Jr., effective Nov. 28, according to […]